IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Michael T. Migawa et al.

Confirmation No.: 2825

Serial No.:

10/592,919

Group Art Unit:

Not assigned

Filed:

9/15/2006

Examiner:

Not Assigned

Title:

COMPOSITIONS AND METHODS FOR OPTIMIZING CLEAVAGE

OF RNA BY RNASE H

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821 THROUGH 1.825

I hereby state that the amendments, made in accordance with 37 C.F.R. § 1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported throughout the application, as filed. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.

I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. § 1.825(b), is the same as the amended paper Sequence Listing.

Respectfully submitted,

Clifford Ford

Registration No. 52,903

Date:

ISIS Pharmaceuticals, Inc. 1896 Rutherford Rd.

Carlsbad, CA 92008

Telephone: (760) 931-9200 Facsimile: (760) 603-3820